Together, these results provide preclinical evidence that targeting the STING pathway with an orally bioactive antagonist could be an effective treatment for NGLY1 deficiency and potentially for many other STING-associated neurodegenerative diseases. Here, NGLY1 is linked to neurodegenerative disease.